LTRN
Lantern Pharma Inc. Common Stock
stockNASDAQ
lantern pharma is leading a wave of innovation in cancer treatment that we believe will bring the best therapies to patients who are most likely to respond. we are pioneering precision medicine approach to cancer by tailoring promising drug programs to the right patients. our approach is to use biomarker based genetic screening to identify and treat patients that would benefit most from our drugs. we believe this approach will reduce the cost of development and increase the speed to market. our strategy is to acquire or partner with promising drug and diagnostic companies to move forward promising personalized medicine programs for cancer patients.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.09 | 2026-09-28 | -16.51% | -10.368 |
| 1M | 1.91 | 2026-09-04 | -52.23% | -2.782 |
| 3M | 3.93 | 2026-07-06 | -76.84% | 1.165 |
| 6M | 1.62 | 2026-04-06 | -43.83% | 2.009 |
| 1Y | 4.11 | 2025-10-03 | -77.86% | 2.625 |
| 2Y | 3.77 | 2024-10-04 | -75.86% | — |
| 5Y | 10.09 | 2021-10-04 | -90.98% | 1.327 |
Lantern Pharma Inc. Common Stock (NASDAQ:LTRN) stock price today is $0.91, and today's volume is 433,629. LTRN is down 9.000% today. The 30 day average volume is 246,166. LTRN market cap is $13.59M with 14.94M shares outstanding.